In this article, we will discuss Trametinib and Colitis and Gastrointestinal Perforation. So, let’s get started.
Trametinib and Colitis and Gastrointestinal Perforation
Colitis and gastrointestinal perforation, including fatal outcomes, have been reported in patients taking Trametinib as a single-agent and when administered with dabrafenib. Across clinical trials of Trametinib, colitis occurred in 0.6% of patients and gastrointestinal perforation occurred in 0.3% of patients. Monitor patients closely for colitis and gastrointestinal perforations.